STOCK TITAN

Structure Therapeutics (GPCR) Stock News, Nov 2025-Apr 2026

GPCR NASDAQ

Structure Therapeutics Inc. develops oral small-molecule therapeutics for chronic metabolic diseases, with a focus on obesity. The clinical-stage global biopharmaceutical company uses a structure-based drug discovery platform and GPCR-targeted pipeline to advance wholly owned compounds, including aleniglipron, an oral nonpeptide GLP-1 receptor agonist, and ACCG-2671, an oral amylin receptor agonist.

Recurring company updates include clinical data from the ACCESS aleniglipron program, obesity and weight-management research presentations, financial results, research-and-development funding, ADS and warrant financings, and leadership or governance changes. The company’s American depositary shares trade under GPCR, with each ADS representing three ordinary shares.

Rhea-AI Summary

Structure Therapeutics (NASDAQ: GPCR) appointed Matthew Lang, J.D. as Chief Operating Officer and General Counsel effective April 14, 2026. Mr. Lang brings 15+ years of global biopharma leadership across legal, corporate strategy, compliance, and business development.

His background includes guiding a company through an up to $10 billion acquisition by Pfizer, leadership roles tied to Phase 3 development and global approvals, and responsibility for ex-US operations; he will support moving aleniglipron into Phase 3 and strengthening operations.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.94%
Tags
none
-
Rhea-AI Summary

Structure Therapeutics (NASDAQ: GPCR) reported positive Phase 2 ACCESS program topline data for oral GLP-1 receptor agonist aleniglipron. Placebo-adjusted mean weight loss at 44 weeks was -16.3% (180 mg) and -16.0% (240 mg); OLE 56-week loss reached -16.2% (120 mg).

Tolerability improved using a 2.5 mg starting dose (AE-related discontinuations 2.0–3.4%). No drug-induced liver injury or QTc prolongation observed across >625 participants. End-of-Phase 2 FDA meeting set for Q2 2026; Phase 3 initiation on track for 2H 2026.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.40%
Tags
-
Rhea-AI Summary

Structure Therapeutics (NASDAQ: GPCR) reported positive Phase 2 aleniglipron results, including a placebo-adjusted 15.3% weight loss at 36 weeks (240 mg) and no observed weight-loss plateau. The company holds $1.4 billion in cash and short-term investments, expected to fund operations through end-2028.

Topline ACCESS II 44-week results are expected in Q1 2026 and a Phase 3 program is planned to start in 2H 2026; ACCG-2671 entered Phase 1 with data due 2H 2026.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.73%
Tags
Rhea-AI Summary

Structure Therapeutics (NASDAQ: GPCR) initiated a first-in-human Phase 1 study of ACCG-2671, an oral once-daily small molecule amylin receptor agonist for the treatment of obesity, on Dec. 17, 2025. ACCG-2671 was designed with the company’s structure-based GPCR drug discovery platform.

Preclinical data reported include potent target engagement, robust weight loss as monotherapy, additional weight loss in combination with a GLP-1 receptor agonist, favorable safety, and PK supporting once-daily dosing. The Phase 1 trial will assess safety, tolerability, pharmacokinetics and pharmacodynamics in healthy volunteers and people with obesity using single-ascending and multiple-ascending dose cohorts.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.82%
Tags
-
Rhea-AI Summary

Structure Therapeutics (NASDAQ: GPCR) closed an upsized underwritten public offering on Dec 11, 2025, selling 9,961,538 ADSs (each ADS = 3 ordinary shares) and pre-funded warrants for 1,538,462 ADSs at $65.00 and $64.9999 respectively.

All securities were sold by the company, including the full exercise of the underwriters' 1,500,000-ADS option, producing gross proceeds of approximately $747.5 million before underwriting discounts, commissions and offering expenses.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.56%
Tags
-
Rhea-AI Summary

Structure Therapeutics (NASDAQ: GPCR) priced an upsized underwritten public offering on Dec 9, 2025 of 8,461,538 ADSs at $65.00 per ADS and pre‑funded warrants for 1,538,462 ADSs at $64.9999. The company expects gross proceeds of approximately $650 million before underwriter fees and expenses. The underwriters have a 30‑day option to buy up to an additional 1,500,000 ADSs. The offering is expected to close on December 11, 2025, subject to customary closing conditions, and is being offered pursuant to an effective Form S‑3 registration statement.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.30%
Tags
Rhea-AI Summary

Structure Therapeutics (NASDAQ: GPCR) announced on December 8, 2025 the commencement of a proposed underwritten public offering to issue and sell $500 million of American depositary shares (ADSs) or, for certain investors, pre-funded warrants to purchase ordinary shares represented by ADSs. Each ADS represents three ordinary shares. The company expects to grant underwriters a 30-day option to purchase up to an additional $75 million of ADSs or pre-funded warrants. The offering is subject to market and other conditions and may not be completed. The offering is being made under an automatic shelf registration statement on Form S-3 filed with the SEC on August 6, 2025, and a preliminary prospectus supplement will be filed and available on SEC.gov.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.63%
Tags
-
Rhea-AI Summary

Structure Therapeutics (NASDAQ: GPCR) reported positive 36‑week topline results for oral GLP‑1 receptor agonist aleniglipron from the ACCESS program supporting Phase 3 entry by mid‑2026. In the Phase 2b ACCESS study aleniglipron 120 mg produced a placebo‑adjusted mean weight loss of 11.3% (27.3 lbs) at 36 weeks (p<0.0001) with AE‑related discontinuations ranging 7.7%–13.3% (mean 10.4%) across active arms. In exploratory ACCESS II, the 240 mg dose achieved placebo‑adjusted mean weight loss up to 15.3% (35.5 lbs) at 36 weeks (p<0.0001). Studies reported GLP‑1 class GI adverse events, no drug‑induced liver injury, no persistent liver enzyme elevations, and no QTc prolongation. Company plans an FDA Type B meeting in H1 2026 and to start Phase 3 by mid‑2026.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
102.49%
Tags
-
Rhea-AI Summary

Structure Therapeutics (NASDAQ: GPCR) will release topline data from its ACCESS clinical program of aleniglipron, a once-daily oral small-molecule GLP-1 receptor agonist for obesity, before market open on Monday, December 8, 2025. Management will host a conference call and webcast to discuss the data at 8:30 a.m. ET the same day.

Investors can access the live webcast via the company Investor Relations events page and obtain phone dial-in details from the provided link. A replay will be posted approximately two hours after the live event and will remain available for 90 days.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
102.49%
Tags
none
Rhea-AI Summary

Structure Therapeutics (NASDAQ: GPCR) reported that topline 36-week data from its oral GLP-1 agonist aleniglipron ACCESS and ACCESS II studies are on track for readouts by year-end 2025. The company expects to initiate a first-in-human Phase 1 study of oral amylin receptor agonist ACCG-2671 by year-end 2025 and has declared a second amylin candidate, ACCG-3535, with preclinical data showing dose-dependent weight loss and reduced food intake in rodent models.

Financials: cash, cash equivalents and short-term investments of $799.0 million as of September 30, 2025, projected to fund operations through at least 2027 (excludes Phase 3 registrational studies). Q3 2025 results: R&D $59.0M, G&A $14.8M, net loss $65.7M.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.88%
Tags

FAQ

What is the current stock price of Structure Therapeutics (GPCR)?

Structure Therapeutics (GPCR) last closed at $16.13.

What is the market cap of Structure Therapeutics (GPCR)?

The market cap of Structure Therapeutics (GPCR) is approximately $1.2B.